Skip to main content Accessibility help
×
Home

What's New in the Medical Management of Pediatric Epilepsy?

  • Elaine C. Wirrell (a1)

Abstract

Epilepsy affects approximately 45 per 100,000 children per year. While many cases respond favorably to antiepileptic therapy, approximately 20% will prove to be medically intractable. This paper reviews some of the recently identified important metabolic and autoimmune etiologies for which there are specific therapies. Additionally, newer antiepileptic medications, including rufinamide, lacosamide, retigabine, eslicarbazepine and brivaracetam and newer dietary options, including the modified Atkins diet and low-glycemic index diet are discussed.

RÉSUMÉ

L'épilepsie atteint environ 45 enfants par 100 000 annuellement. Bien que plusieurs patients répondent favorablement au traitement antiépileptique, environ 20% ont une épilepsie pharmacorésistante. Cet article revoit certaines des étiologies métaboliques et autoimmunes importantes identifiées récemment, pour lesquelles il existe un traitement spécifique. De plus, nous traitons des nouveaux médicaments antiépileptiques dont le rufinamide, le lacosamide, la rétigabine, l'eslicarbazépine et le brivaracetam et de nouvelles options diététiques dont le régime Atkins modifié et la diète à indice glycémique faible.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      What's New in the Medical Management of Pediatric Epilepsy?
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      What's New in the Medical Management of Pediatric Epilepsy?
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      What's New in the Medical Management of Pediatric Epilepsy?
      Available formats
      ×

Copyright

Corresponding author

Child and Adolescent Neurology, Mayo Clinic, 200 First St SW, Rochester, Minnesota, 55905, USA. Email: wirrell.elaine@mayo.edu

References

Hide All
1. Camfield, CS, Camfield, PR, Gordon, K, Wirrell, E, Dooley, JM. Incidence of epilepsy in childhood and adolescence: a population-based study in Nova Scotia from 1977 to 1985. Epilepsia. 1996;37:1923.
2. Wirrell, EC, Grossardt, BR, Wong-Kisiel, LC, Nickels, KC. Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study. Epilepsy Res. 2011;95:11018.
3. Brorson, LO, Wranne, L. Long-term prognosis in childhood epilepsy: survival and seizure prognosis. Epilepsia. 1987;28:32430.
4. Camfield, C, Camfield, P, Gordon, K, Smith, B, Dooley, J. Outcome of childhood epilepsy: a population-based study with a simple predictive scoring system for those treated with medication. J Pediatr. 1993;122:8618.
5. Berg, AT, Berkovic, SF, Brodie, MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51:67685.
6. Snead, OC, 3rd, Hosey, LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med. 1985;313:916921.
7. Genton, P. When antiepileptic drugs aggravate epilepsy. Brain Dev. 2000;22:7580.
8. DiMario, FJ Jr, Clancy, RR. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediatr Neurol. 1988;4:24951.
9. Stockler, S, Plecko, B, Gospe, SM Jr, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab. 2011;104:4860.
10. Wolf, B, Heard, GS, Weissbecker, KA, McVoy, JR, Grier, RE, Leshner, RT. Biotinidase deficiency: initial clinical features and rapid diagnosis. Ann Neurol. 1985;18:61417.
11. Wang, D, Pascual, JM, De Vivo, D. Glucose Transporter Type 1 Deficiency Syndrome. 1993.
12. Suls, A, Mullen, SA, Weber, YG, et al. Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1. Ann Neurol. 2009;66:41519.
13. Mullen, SA, Suls, A, De Jonghe, P, Berkovic, SF, Scheffer, IE. Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency. Neurology. 2010;75:43240.
14. Urbizu, A, Cuenca-Leon, E, Raspall-Chaure, M, et al. Paroxysmal exercise-induced dyskinesia, writer’s cramp, migraine with aura and absence epilepsy in twin brothers with a novel SLC2A1 missense mutation. J Neurol Sci. 2010;295:11013.
15. Newmeyer, A, Cecil, KM, Schapiro, M, Clark, JF, Degrauw, TJ. Incidence of brain creatine transporter deficiency in males with developmental delay referred for brain magnetic resonance imaging. J Dev Behav Pediatr. 2005;26:27682.
16. Stockler, S, Schutz, PW, Salomons, GS. Cerebral creatine deficiency syndromes: clinical aspects, treatment and pathophysiology. Subcell Biochem. 2007;46:14966.
17. Ramaekers, VT, Blau, N. Cerebral folate deficiency. Dev Med Child Neurol. 2004;46:84351.
18. Hyland, K. Neurochemistry and defects of biogenic amine neurotransmitter metabolism. J Inherit Metab Dis. 1999;22:35363.
19. Hyland, K, Arnold, LA. Value of lumbar puncture in the diagnosis of infantile epilepsy and folinic acid-responsive seizures. J Child Neurol. 2002;17 Suppl 3:3S4855; discussion 43S56.
20. Bien, CG, Scheffer, IE. Autoantibodies and epilepsy. Epilepsia 2011;52 Suppl 3:1822.
21. Wong-Kisiel, LC, McKeon, A, Wirrell, E. C. Autoimmune Encephalopathies and Epilepsies in Children and Teenagers. Can J Neurol Sci. 2012;in press.
22. Dalmau, J, Gleichman, AJ, Hughes, EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:10918.
23. Hancock, E, Osborne, JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol. 1999;14:714.
24. Chiron, C, Dulac, O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52 Suppl 2:725.
25. Gross-Selbeck, G. Treatment of “benign” partial epilepsies of childhood, including atypical forms. Neuropediatrics. 1995;26:4550.
26. Wirrell, E, Ho, AW, Hamiwka, L. Sulthiame therapy for continuous spike and wave in slow-wave sleep. Pediatr Neurol. 2006;35:2048.
27. Coppola, G. Update on rufinamide in childhood epilepsy. Neuropsychiatr Dis Treat. 2011;7:399407.
28. Resnick, T, Arzimanoglou, A, Brown, LW, et al. Rufinamide from clinical trials to clinical practice in the United States and Europe. Epileptic Disord. 2011;13 Suppl 1:S2743.
29. Verrotti, A, Loiacono, G, Ballone, E, Mattei, PA, Chiarelli, F, Curatolo, P. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. Pediatr Neurol. 2011;44:3479.
30. Glauser, T, Kluger, G, Sachdeo, R, Krauss, G, Perdomo, C, Arroyo, S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70:19508.
31. Kluger, G, Glauser, T, Krauss, G, Seeruthun, R, Perdomo, C, Arroyo, S. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand. 2010;122:2028.
32. Coppola, G, Grosso, S, Franzoni, E, et al. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. Seizure. 2010;19:58791.
33. Kluger, G, Kurlemann, G, Haberlandt, E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav. 2009;14:4915.
34. Vendrame, M, Loddenkemper, T, Gooty, VD, et al. Experience with rufinamide in a pediatric population: a single center’s experience. Pediatr Neurol. 2011;43:1558.
35. Brodie, MJ, Rosenfeld, WE, Vazquez, B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia. 2009;50:1899909.
36. Schimpf, R, Veltmann, C, Papavassiliu, T, et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm. 2012;in press.
37. Chu-Shore, CJ, Thiele, EA. New drugs for pediatric epilepsy. Semin Pediatr Neurol. 2010;17:21423.
38. Ben-Menachem, E, Biton, V, Jatuzis, D, Abou-Khalil, B, Doty, P, Rudd, GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48:130817.
39. Halasz, P, Kalviainen, R, Mazurkiewicz-Beldzinska, M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:44353.
40. Chung, S, Sperling, MR, Biton, V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51:95867.
41. Heyman, E, Lahat, E, Levin, N, Berkovitch, M, Gandelman-Marton, R. Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur J Paediatr Neurol. 2012;16:1519.
42. Guilhoto, LM, Loddenkemper, T, Gooty, VD, et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol. 2011;44:41419.
43. Hofler, J, Unterberger, I, Dobesberger, J, Kuchukhidze, G, Walser, G, Trinka, E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;52:e14852.
44. Goodwin, H, Hinson, HE, Shermock, KM, Karanjia, N, Lewin, JJ, 3rd. The use of lacosamide in refractory status epilepticus. Neurocrit Care. 2011;14:34853.
45. Rantsch, K, Walter, U, Wittstock, M, Benecke, R, Rosche, J. Efficacy of intravenous lacosamide in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Seizure. 2011;20:52932.
46. Nizam, A, Mylavarapu, K, Thomas, D, et al. Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy. Epilepsia. 2011;52:e1535.
47. Stafstrom, CE, Grippon, S, Kirkpatrick, P. Ezogabine (retigabine). Nat Rev Drug Discov 2011;10:72930.
48. Fattore, C, Perucca, E. Novel medications for epilepsy. Drugs. 2011;71:215178.
49. French, JA, Abou-Khalil, BW, Leroy, RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76:155563.
50. Brodie, MJ, Lerche, H, Gil-Nagel, A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010;75:181724.
51. Ben-Menachem, E, Gabbai, AA, Hufnagel, A, Maia, J, Almeida, L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89:27885.
52. Almeida, L, Minciu, I, Nunes, T, et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol. 2008;48:96677.
53. French, JA, Costantini, C, Brodsky, A, von Rosenstiel, P. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010;75:51925.
54. Malykh, AG, Sadaie, MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70:287312.
55. Perucca, E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia. 2009;50 Suppl 12:4950.
56. Kossoff, EH, Krauss, GL, McGrogan, JR, Freeman, JM. Efficacy of the Atkins diet as therapy for intractable epilepsy. Neurology. 2003;61:178991.
57. Pfeifer, HH, Thiele, EA. Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. Neurology. 2005;65:181012.
58. Kossoff, EH, McGrogan, JR, Bluml, RM, Pillas, DJ, Rubenstein, JE, Vining, EP. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. Epilepsia. 2006;47:4214.
59. Kumada, T, Miyajima, T, Oda, N, Shimomura, H, Saito, K, Fujii, T. Efficacy and tolerability of modified Atkins diet in Japanese children with medication-resistant epilepsy. Brain Dev. 2012;34:328.
60. Miranda, MJ, Mortensen, M, Povlsen, JH, Nielsen, H, Beniczky, S. Danish study of a modified Atkins diet for medically intractable epilepsy in children: can we achieve the same results as with the classical ketogenic diet? Seizure. 2011;20:1515.
61. Kossoff, EH, Bosarge, JL, Miranda, MJ, Wiemer-Kruel, A, Kang, HC, Kim, HD. Will seizure control improve by switching from the modified Atkins diet to the traditional ketogenic diet? Epilepsia. 2010;51:24969.
62. Muzykewicz, DA, Lyczkowski, DA, Memon, N, Conant, KD, Pfeifer, HH, Thiele, EA. Efficacy, safety, and tolerability of the low glycemic index treatment in pediatric epilepsy. Epilepsia. 2009;50:111826.
63. Coppola, G, D’Aniello, A, Messana, T, et al. Low glycemic index diet in children and young adults with refractory epilepsy: first Italian experience. Seizure. 2011;20:5268.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed